Table 3 Grade 3 and 4 adverse events

From: Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme

Grade 3 or 4 toxicity

IFN study ( N =33): n (%)

PEG study ( N =29): n (%)

Leucopoenia

12 (35)

11 (38)

Thrombocytopoenia

6 (18)

6 (21)

Fatigue

6 (18)

6 (18)

Pulmonary embolus/thrombosis

0 (0)

5 (17)

Nausea/vomiting

2 (6)

0 (0)

Headache

0 (0)

2 (7)

Incontinence

0 (0)

2 (7)

Other

2 (3)a

8 (3)b

  1. aOne instance each of diarrhoea and elevated transaminases.
  2. bOne instance each of anaemia, confusion, depression, hypotension, hypoxemia, infection, lymphopoenia, and pruritis.
Back to article page